Clinical Trial Update: An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy

View source ↗

Summary

Completed observational study assessing epoetin beta (NeoRecormon) for anemia in patients with non-myeloid malignancy; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• NeoRecormon (epoetin beta)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Status: COMPLETED | Results posted: 2016-02-09